Viatris announces the sale of its equity stake in Biocon Biologics for $815 million in total consideration.
The transaction accelerates the expiration of biosimilars non-compete restrictions.
The deal includes $400 million in cash and $415 million in equity shares of Biocon.
Transaction Details
Viatris to receive $400 million in cash and $415 million in equity shares of Biocon Limited.
Acceleration of Expiration
Non-compete restrictions on Viatris expiring immediately for ex-U.S. markets and in November 2026 for U.S. markets.
Strategic Evolution
Monetizing the equity stake provides additional optionality for Viatris' future growth.
- The sale boosts Viatris' financial position with a significant cash influx.
- Regaining access to the biosimilars market globally enhances Viatris' strategic capabilities.
The agreement marks a pivotal step in Viatris' evolution, opening up new growth opportunities and strengthening its position in the healthcare sector.